Alex Azar in 2006 as deputy secretary of health and human services. / Image: Evan Vucci/AP
A recent New York Times article noted President Trump’s recent nomination for secretary of health and human services, the role responsible for regulating the pharmaceutical industry. Trump’s choice is Alex M. Azar II, who previously held the position of president of the American division of Eli Lilly as well a health official in George W. Bush’s administration.
Should his position be confirmed, Azar will replace Tom Price who recently resigned after he was found out for consistently using chartered jets for government-related travel. Democrats are skeptical the former pharmaceutical executive can effectively lower drug prices given President Trump’s pattern of putting ex-industry officials in charge of regulating their former colleagues.
Companies in this article
